Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12348026 | 0.94 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3TAAR1ADRB2 | |
| SCHEMBL16380617 | 0.92 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3TAAR1CHRNA7 | |
| SCHEMBL1978757 | 0.90 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3CHRNA7KCNH2 | |
| SCHEMBL13114042 | 0.90 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3TAAR1ADRB2 | |
| SCHEMBL14493818 | 0.87 | SLC6A2 (0.46) | SLC6A4SLC6A2SLC6A3CHRNA7ALDH1A1 | |
| SCHEMBL29321255 | 0.80 | TAAR1 (0.61) | SLC6A4SLC6A2SLC6A3TAAR1ADRB2 | |
| SCHEMBL28338265 | 0.80 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3TAAR1ADRB2 | |
| SCHEMBL5244808 | 0.80 | TAAR1 (0.61) | SLC6A4SLC6A2SLC6A3TAAR1ADRB2 | |
| SCHEMBL29321256 | 0.80 | TAAR1 (0.61) | SLC6A4SLC6A2SLC6A3TAAR1ADRB2 | |
| SCHEMBL2295214 | 0.78 | KDM4E (0.68) | SLC6A4SLC6A2SLC6A3TAAR1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924391-B2 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-20050043370-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2005-02-24 | — | — | US | disclosed |
| US-6803378-B2 | FOR THERAPY AND PROPHYLAXIS OF ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), OR ARC | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-12 | — | — | US | disclosed |
| US-20030181490-A1 | HIV integrase inhibitors | WALKER MICHAEL A (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322599-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030027847-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-02-06 | — | — | US | disclosed |
| US-6492550-B2 | INHIBITORS OF THE CYTOSOLIC PHOSPHOLYPASE A2 ENZYMES | BRISTOL-MYERS SQUIBB COMPANY | 2002-12-10 | — | — | US | disclosed |
| WO-2001096283-A9 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020068722-A1 | Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-06 | — | — | US | disclosed |
| US-20020037875-A1 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-03-28 | — | — | US | disclosed |
| US-6350892-B1 | ENZYME INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-26 | — | — | US | disclosed |
| WO-2001096283-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043370-A1 | HIV integrase inhibitors | AKR1C3, CBR3, CBR1 | SLC6A4 3455/4885SLC6A2 2616/4885SLC6A3 1642/4885 |
| US-20020037875-A1 | Alpha-amino,-thio,-oxo substituted ketones as phospholipase inhibitors | PLA2G4B, PLA2G4A, PLA2G1B | SLC6A4 4308/4885SLC6A2 4591/4885SLC6A3 4669/4885 |
| US-20020068722-A1 | Alpha-substituted thio,-oxo trifluoromethylketones as phospholipase inhibitors | PLA2G4B, PLA2G4A, PLA2G1B | SLC6A4 4575/4885SLC6A2 4775/4885SLC6A3 4773/4885 |
| US-20030181490-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | SLC6A4 3867/4885SLC6A2 3427/4885SLC6A3 2433/4885 |
| US-20030027847-A1 | HIV integrase inhibitors | CBR1, CCR5, CCR1 | SLC6A4 3867/4885SLC6A2 3427/4885SLC6A3 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.